ACHV READ THE FULL ACHV RESEARCH REPORT 3Q:24 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2024 results in a November 7th press release ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning and welcome to Ocugen’s Third Quarter 2024 Financial ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

RenovoRx, Inc. ("RenovoRx” or the "Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery ...

Detailed price information for Intra-Cellular Ther (ITCI-Q) from The Globe and Mail including charting and trades.

Upon FDA approval of acoramidis, it is our intent to honor the courage of our U.S. clinical trial patients by providing them acoramidis free for life ... be applied to another therapy in the Company’s ...

We are collecting these data in our Phase 3 trials and other non-trial activities ... T-cell therapy and immunostimulator combination, unlike other cellular therapy approaches, requires no cellular ...